A new approach to corrector therapies

Protein misfolding causes devastating diseases that affect millions of people. Small-molecule correctors are a proven way to treat them, but they have mostly been developed for diseases where a few common mutations cover most patients. We design correctors to work across many mutations from the start, testing them in engineered human cells that carry the mutations patients have.

Our pipeline

Small-molecule medicines for genetic disease, cancer and other serious diseases.

Hit IDHit to LeadLead OptIND-enablingClinical
Collaboration

Correctors / genetic disease

RHO-associated adRPOCT-980Phase 1b/2
Fabry diseaseLead Optimization
Undisclosed neurodegenerationHit IDBristol Myers Squibb

Oncology

p53-mutant cancersHit to Lead
HPV-induced cancersHit IDGates Foundation

Metabolism

MC4RLead Optimization
UndisclosedHit ID

OCT-980

An investigational oral corrector for retinitis pigmentosa.

Phase 1b/2 in patients with RHO-adRP

FDA Orphan Drug Designation for retinitis pigmentosa

Retinitis pigmentosa causes progressive vision loss and can lead to blindness. In RHO-adRP, one of the most common forms of RP with no approved treatment, misfolded rhodopsin mislocalizes within rod cells, accumulating to toxic levels. OCT-980 is designed to stabilize misfolded rhodopsin and restore rhodopsin trafficking.

View the studyClinicalTrials.govNCT07408232

How OCT-980 is designed to work

Untreated, misfolded rhodopsin accumulates to toxic levels in the rod cell. OCT-980 is designed to bind and stabilize it, so it can fold and continue to its destination.

Discovered in engineered human cells

Misfolded rhodopsin can only be studied in living cells, so we engineered human cells that report whether a molecule restores rhodopsin trafficking.

We made and screened more than 250,000 molecules directly in those cells to design an oral, potent corrector that reaches the retina. During that campaign, low-potency early compounds became OCT-980.

Tested against every possible variant

RHO-adRP is caused by many different rhodopsin mutations. In our engineered-cell assays, OCT-980 rescues most misfolding rhodopsin variants.

One medicine needs to work across as many variants as possible, so we measured all 6,612 possible single amino-acid changes in rhodopsin, with and without OCT-980. Our complete map of the mistrafficking of rhodopsin is published in Science Advances.

Laboratory condition

Different mutations disrupt the same protein. Each square is one rhodopsin variant, measured in engineered human cells without and with OCT-980. Learn more about deep mutational scans

Lower traffickingHigher trafficking
No drug selected.

Improves retinal structure in animal models

In animal models, OCT-980 improves retinal structure and slows the loss of rod cells.

Without treatment, misfolded rhodopsin is mistrafficked within rod cells, and the photoreceptor layer thins. With OCT-980, more rhodopsin reaches its destination and more of the photoreceptor layer is preserved.

HealthyHealthy retina: a thick green band of rhodopsin in the outer segments above a thick blue layer of photoreceptor nuclei.
UntreatedUntreated disease model: a thin green band, yellow rhodopsin stuck in the ER below it and among the blue nuclei, and a thinner layer of photoreceptor nuclei.
With OCT-980Disease model treated with OCT-980: a continuous green band, little yellow, and a thicker layer of photoreceptor nuclei than untreated.
Retinal cross-sections from a preclinical animal model. Untreated, more rhodopsin is stuck in the endoplasmic reticulum (ER), where the cell folds new proteins, and less reaches the outer segments.

Discovery programs

Built in-house on the Navigator.

Misfolded enzymeFolded enzymeOur molecule

Fabry disease

Lead Optimization

A better oral treatment, for more people with Fabry disease.

Fabry disease damages the kidneys, heart and nervous system, and today’s treatments leave much of that burden in place. We are building an oral corrector that stabilizes α‑galactosidase A without blocking its activity, aiming to treat new patients and better treat those already being treated.

Mutant p53, unable to bind DNAp53 bound to DNAOur moleculeDNA

p53-mutant cancers

Hit to Lead

Switch p53 back on in the cancers that disable it.

TP53 is the most frequently mutated gene in cancer, altered in about half of all tumors. We are building multi-variant correctors designed to restore mutant p53’s proper interaction with DNA, aimed at a class of mutations that affects many forms of cancer.

Built through experiments in living cells

Our platform connects engineered cellular assays, parallel chemistry and computational learning to guide the next experiments.

Explore our technology

Let’s advance medicines together

Connect with us about our programs and scientific partnerships.

ahoy@octant.bio